706 documents

Read All
21:53 , May 29, 2019 |  BC Extra  |  Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...
Read More
22:28 , Aug 9, 2018 |  BC Extra  |  Company News

Management tracks: Grail, Celyad, Hua

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Hal Barron and Hans Bishop to its board. Barron is CSO and president of R&D at GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), and Bishop was president and CEO...
Read More
00:14 , Dec 28, 2017 |  BC Extra  |  Company News

Management tracks: Vivus, Peregrine

Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King, a director, will serve as interim CEO as the company seeks a permanent replacement. King was president and...
Read More
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
Read More
00:41 , Mar 25, 2017 |  BioCentury  |  Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
Read More
21:47 , Mar 3, 2017 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least five biotechs and pharmas are expected to report earnings this week. (A) Reported and estimated EPS for 12 months Company Date Pre/post mkt 4Q16 EPS est 4Q15 EPS Expected chg...
Read More
20:30 , Jan 13, 2017 |  BC Week In Review  |  Company News

Selten, Vivus deal

Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering the drugs from Stanford University (Stanford,...
Read More
23:46 , Nov 4, 2016 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 12 biotechs and pharmas are expected to report earnings this week. (A) Nine-month EPS; (B) Fiscal 2Q; (C) First half EPS Company Date Pre/post mkt 3Q16 EPS est 3Q15 EPS...
Read More
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Vivus, Mist Pharmaceuticals deal

Vivus granted Mist’s Metuchen Pharmaceuticals LLC affiliate exclusive rights to commercialize erectile dysfunction drug Stendra avanafil in the U.S., Canada, South America and India. Vivus will receive $70 million up front. Metuchen will be responsible...
Read More
07:00 , Aug 1, 2016 |  BioCentury  |  Finance

Gilead's arithmetic problem

Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to...
Read More